Atea Pharmaceuticals, Inc. — Director's Dealing 2025

Feb 5, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2025-01-31

Reporting Person: Sommadossi Jean-Pierre (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-31	Common Stock	M	173467	—	Acquired	290024	Direct
2025-01-31	Common Stock	A	99517	—	Acquired	389541	Direct
2025-01-31	Common Stock	F	88601	$3.06	Disposed	300940	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-31	Restricted Stock Units	$	M	173467	Disposed		Common Stock (173467)	Direct
2025-01-31	Restricted Stock Units	$	A	99518	Acquired		Common Stock (99518)	Direct
2025-01-31	Stock Option (Right to Buy)	$3.06	A	440000	Acquired	2035-01-30	Common Stock (440000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5866025	Indirect

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs").

F3: The original grant of 520,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.

F4: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.

F5: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029.